- Home
- HTH vs MNKD Comparison
HTH vs MNKD Comparison
Compare HTH & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTH
- MNKD
- Stock Information
- Founded
- HTH 1998
- MNKD 1991
- Country
- HTH United States
- MNKD United States
- Employees
- HTH N/A
- MNKD N/A
- Industry
- HTH Major Banks
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- HTH Finance
- MNKD Health Care
- Exchange
- HTH Nasdaq
- MNKD Nasdaq
- Market Cap
- HTH 1.8B
- MNKD 1.9B
- IPO Year
- HTH 2004
- MNKD 2004
- Fundamental
- Price
- HTH $28.91
- MNKD $6.01
- Analyst Decision
- HTH Hold
- MNKD Buy
- Analyst Count
- HTH 2
- MNKD 6
- Target Price
- HTH $34.50
- MNKD $8.92
- AVG Volume (30 Days)
- HTH 354.3K
- MNKD 2.7M
- Earning Date
- HTH 01-27-2025
- MNKD 02-25-2025
- Dividend Yield
- HTH 2.35%
- MNKD N/A
- EPS Growth
- HTH N/A
- MNKD N/A
- EPS
- HTH 1.63
- MNKD 0.08
- Revenue
- HTH $1,169,826,000.00
- MNKD $267,200,000.00
- Revenue This Year
- HTH N/A
- MNKD $45.45
- Revenue Next Year
- HTH $0.79
- MNKD $16.45
- P/E Ratio
- HTH $17.73
- MNKD $75.81
- Revenue Growth
- HTH N/A
- MNKD 51.35
- 52 Week Low
- HTH $26.67
- MNKD $3.17
- 52 Week High
- HTH $35.32
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- HTH 47.61
- MNKD 37.75
- Support Level
- HTH $26.67
- MNKD $5.98
- Resistance Level
- HTH $29.11
- MNKD $6.32
- Average True Range (ATR)
- HTH 0.63
- MNKD 0.21
- MACD
- HTH 0.17
- MNKD -0.04
- Stochastic Oscillator
- HTH 85.31
- MNKD 20.55
About HTH Hilltop Holdings Inc.
Hilltop Holdings Inc is a Dallas-based financial holding company. Its primary line of business is to provide business and consumer banking services from offices throughout Texas through the PlainsCapital Bank. The company also provides other financial products and services through its broker-dealer and mortgage origination segments. The company generates a majority of its revenue through its banking operations.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.